Oman
Tuberculosis profile
Population  2012 3.3 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.031 (0–0.3) 0.92 (0–9)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.07 (0.05–0.08)
Prevalence  (includes HIV+TB) 0.6 (0.26–1.1) 18 (7.8–33)
Incidence  (includes HIV+TB) 0.44 (0.38–0.5) 13 (12–15)
Incidence (HIV+TB only) 0.014 (0.013–0.016) 0.43 (0.38–0.49)
Case detection, all forms (%) 87 (77–99)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 205 (55) Relapse 7 (88)
Smear-negative 39 (10) Treatment after failure 0 (0)
Smear-unknown / not done 0 (0) Treatment after default 0 (0)
Extrapulmonary 131 (35) Other 1 (13)
Other 0 (0)      
Total new 375   Total retreatment 8  
           
Other (history unknown) 0        
Total new and relapse 382   Total cases notified 383  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.2 1.3 1.3
Age < 15 0 5 9
Laboratories 2012
Smear (per 100 000 population) 7.5
Culture (per 5 million population) 13.6
Drug susceptibility testing (per 5 million population) 1.5
Is second-line drug susceptibility testing available? Yes, in country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 97   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 99  
Retreatment 67  
TB/HIV 2012 Number (%)
TB patients with known HIV status 383 (100)
HIV-positive TB patients 14 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 14 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 14 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.4 (0.89–5.2) 0 (0–37)
MDR-TB cases among notified pulmonary
TB cases
6 (2–13) 0 (0–3)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 248 (102%) 8 (100%) 256
Laboratory-confirmed MDR-TB cases 6 0 6
Patients started on MDR-TB treatment     6
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data